As of March 31, 2014, PHARMAGEN INC carries a market capitalization of 1.92M, placing it among publicly traded companies globally. Its enterprise value stands at 7.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.92M |
| Enterprise Value | 7.39M |
As of March 31, 2014, PHARMAGEN INC has 504.45M shares outstanding.
| Shares Outstanding | 504.45M |
These figures are as of March 31, 2014. The price-to-sales ratio is 0.36, and the price-to-book ratio stands at -0.24.
| PS Ratio | 0.36 |
| PB Ratio | -0.24 |
| P/TBV Ratio | -0.24 |
| P/FCF Ratio | -2.71 |
| P/OCF Ratio | -3.29 |
These figures are as of March 31, 2014. The EV/Sales ratio of 1.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.39M versus a market cap of 1.92M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.67 |
As of March 31, 2014, PHARMAGEN INC maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -71.34, indicating conservative leverage, while an interest coverage ratio of -1.19 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.10 |
| Quick Ratio | 0.07 |
| Debt / Equity | -71.34 |
| Debt / EBITDA | -1.60 |
| Interest Coverage | -1.19 |
These figures cover the twelve months ended March 31, 2014. Return on assets (ROA) is negative at -246.83, reflecting losses generated across the asset base. The company generates approximately 2.21M in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.45 indicates how many times PHARMAGEN INC sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -246.83 |
| Revenue Per Employee | 2.21M |
| Employee Count | 2.00 |
| Inventory Turnover | 9.45 |
As of the close on November 16, 2026, PHARMAGEN INC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at -NaN, while the 200-day moving average is 0.00.
| 50-Day Moving Average | -NaN |
Over the twelve months ended March 31, 2014, PHARMAGEN INC generated 4.41M in revenue and converted that into -5.87M in net income, yielding earnings per share of -0.01. EBITDA reached -3.59M, while operating income came in at -2.24M.
| Revenue | 4.41M |
| Gross Profit | 2.75M |
| Operating Income | -2.24M |
| Net Income | -5.87M |
| EBITDA | -3.59M |
| EBIT | -3.69M |
| Earnings Per Share (EPS) | -0.01 |
As of March 31, 2014, PHARMAGEN INC holds 264,673.00 in cash and equivalents against 5.73M in total debt, resulting in a net debt position of 5.15M. Total book value stands at -8.03M, with working capital of -7.46M providing operational flexibility.
| Cash & Cash Equivalents | 264,673.00 |
| Total Debt | 5.73M |
| Net Debt | 5.15M |
| Equity (Book Value) | -8.03M |
| Book Value Per Share | -0.02 |
| Working Capital | -7.46M |
PHARMAGEN INC produced -483,093.00 in operating cash flow over the twelve months ended March 31, 2014. After subtracting -102,607.00 in capital expenditures, free cash flow totaled -585,700.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -483,093.00 |
| Capital Expenditures | -102,607.00 |
| Free Cash Flow | -585,700.00 |
Over the twelve months ended March 31, 2014, PHARMAGEN INC posted a gross margin of 62.35, reflecting its pricing power and cost economics. The operating margin of -50.83 and net profit margin of -133.10 provide insight into operational efficiency.
| Gross Margin | 62.35 |
| Operating Margin | -50.83 |
| Profit Margin | -133.10 |
| EBITDA Margin | -81.36 |
These figures cover the twelve months ended March 31, 2014. The dividend payout ratio of 1.67 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -36.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.61, meaning PHARMAGEN INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Payout Ratio | 1.67 |
| Shareholder Yield | -10.61 |
| FCF Yield | -36.90 |
PHARMAGEN INC's most recent stock split took place on December 7, 2011 with a 1:45 split ratio.
| Last Split Date | 12/7/2011 |
| Split Ratio | 1:45 |
As of March 31, 2014, PHARMAGEN INC has an Altman Z-Score of -20.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.29 |